EP1223939A1 - Method of treating weight gain - Google Patents

Method of treating weight gain

Info

Publication number
EP1223939A1
EP1223939A1 EP00927593A EP00927593A EP1223939A1 EP 1223939 A1 EP1223939 A1 EP 1223939A1 EP 00927593 A EP00927593 A EP 00927593A EP 00927593 A EP00927593 A EP 00927593A EP 1223939 A1 EP1223939 A1 EP 1223939A1
Authority
EP
European Patent Office
Prior art keywords
quetiapine
patient
pharmaceutically acceptable
weight
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00927593A
Other languages
German (de)
French (fr)
Inventor
Michael J. Forest Hospital/Rush Pres. REINSTEIN
Andrew Martin Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911499.3A external-priority patent/GB9911499D0/en
Priority claimed from GB0002762A external-priority patent/GB0002762D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP1223939A1 publication Critical patent/EP1223939A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • This invention relates to a method of treating the weight of patients and is particularly concerned with a method of treating the weight of patients suffering from psychoses.
  • Schizophrenia is a chronic and debilitating illness that affects approximately 1% of the population worldwide.
  • conventional antipsychotic agents have been widely used to treat schizophrenia; however, they are associated with undesirable motor symptoms (extrapyramidal symptoms [EPS]) such as akathisia, dyskinesia, bradykinesia and parkinsonism, which are known to contribute to poor compliance with treatment.
  • EPS extrapyramidal symptoms
  • Such adverse effects of the older, typical antipsychotics caused a great deal of distress to patients but were tolerated as being inevitable in the treatment of psychotic symptoms.
  • Weight gain is associated with increased morbidity and mortality from a wide range of conditions including hypertension, coronary heart disease, cerebrovascular disease, type 2 diabetes mellitus, various cancers, sleep apnea and respiratory problems. It is also linked with morbidity related to the disease being treated itself. Studies have shown that the side effect of weight gain causes relatively more distress than many of the other common side effects associated with antipsychotic medication (Weiden, 1999). If weight gain is considered by the patient to be unacceptable, compliance with the antipsychotic may be reduced and a worsening of the psychotic condition may ensue.
  • this report is based on an extrapolation to a ten week period based on an estimate at week 6 of treatment.
  • quetiapine is associated with a small mean weight increase in the first 5-6 weeks of treatment with little further mean change observed over 12 months of treatment.
  • Actual mean weight increase for quetiapine treated patients differs markedly from the extrapolated figures reported by Simansky et al.
  • a method of treating the weight of a patient which comprises administering an effective amount of quetiapine or a pharmaceutically acceptable salt thereof to said patient.
  • the present invention provides quetiapine or a pharmaceutically acceptable salt thereof for use in treating the weight of a patient.
  • the present invention provides the use of quetiapine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating the weight of a patient.
  • Quetiapine is l l-(4-[2-(2-hydroxyethoxy)ethyl]-l-piperazinyl)- dibenzo[b,fJ[1.4]thiazepine.
  • This compound pharmaceutically acceptable salts thereof and use in treating schizophrenia are described in granted European Patent No. EP 240,228.
  • the patient is suffering from psychoses. It is well recognized that there is a link between obesity and diabetes, especially type IT diabetes, and that moderate to severe obesity increases the risk of developing diabetes. It is also widely accepted that weight loss results in metabolic improvement and hence in glycaemic control and insulin sensitivity which in turn give rise to improvements in cardiovascular risk factors. This is reported by, for example, Bosello et al, Int. J. of Obesity,
  • the present invention further provides a method of treating the weight of a patient who is exhibiting diabetes or is at risk from developing diabetes which method comprises administering an effective amount of quetiapine or a pharmaceutically acceptable salt thereof to said patient.
  • the patient is suffering from psychoses.
  • a method of treating psychoses in a patient who is diabetic or who is at risk from developing diabetes comprises administering an effective amount of quetiapine or a pharmaceutically acceptable salt thereof to said patient.
  • the patient is diabetic, that is exhibiting one or more of the symptoms of diabetes.
  • Quetiapine and pharmaceutically acceptable salts thereof are particularly effective in inducing weight loss in patients who have tended to gain weight when treated with other antipsychotics such as clozapine or olanzapine, in particular clozapine. Under such circumstances, quetiapine or pharmaceutically acceptable salts thereof may reverse at least part of any weight gained as a result of treatment with the antipsychotic such as clozapine or olanzapine, in particular clozapine.
  • the dosage of the other antipsychotic agent such as clozapine or olanzapine, is decreased during treatment with quetiapine or pharmaceutically acceptable salt thereof.
  • the method of treatment of the present invention relates to short term (5-6 weeks), medium term (1-6 months) and long term (6 months-2 years or more) treatment, and is particularly valuable in medium term and long term treatment.
  • Quetiapine may be administered as the compound, 1 l-(4-[2-(2-hydroxyethoxy)ethyl]- l-piperazinyl)-dibenzo[b,f][1.4]thiazepine or may be administered in the form of a pharmaceutically acceptable salt.
  • suitable salts include, for example, chloride, maleate, fumarate, citrate, phosphate, methane sulphonate and sulphate salts.
  • Preferred salts include fumarates and a particularly preferred salt is the hemi-fumarate.
  • 1 l-(4-[2-(2-hydroxyethoxy)ethyl]-l-piperazinyi)- dibenzo[b,f][1.4]thiazepine is administered in the form of a pharmaceutically acceptable salt, and in particular a fumarate (2:1) salt.
  • quetiapine or a pharmaceutically acceptable salt may be administered orally or parenterally in a conventional dosage form such as tablets, pills, capsules, injectables or the like.
  • a conventional dosage form such as tablets, pills, capsules, injectables or the like.
  • the dosage in mg/kg of body weight of the compound used to treat mammals will vary according to the size of the mammal and particularly with respect to the brain/body weight ratio. In general, a higher mg/kg dosage for a small animal such as a dog will have the same effect as a lower mg/kg dosage in an adult human.
  • a minimum effective dosage for quetiapine or a pharmaceutically acceptable salt thereof will be at least about 1.0 mg/kg of body weight per day for mammals with a maximum dosage for a small mammal such as a dog, of about 200 mg/kg per day.
  • a dosage of about 1.0 to 40 mg/kg per day will generally be effective.
  • a dosage of about 25mg to 800mg per day will generally be effective.
  • a dosage of about 150mg to 750mg per day will be administered, with a convenient dosage being about 300mg per day. In some groups of patients a lower dosage may be preferred such as lOOmg per day.
  • the dosage can be given once daily or in divided doses, for example, 2 to 4 doses daily.
  • the dose may be conventionally formulated in an oral or parenteral dosage form by compounding 25 to 500 mg per unit dosage of conventional vehicle, excipient, binder, preservative, stabilizer, flavor or the like as called for by accepted pharmaceutical practice, for example, as described in US Patent 3,755,340.
  • Quetiapine or a pharmaceutically acceptable salt may be used in pharmaceutical compositions as the sole active ingredient or may be contained in a pharmaceutical composition together with one or more other active ingredients, or it may be co-administered with one or more known drugs.
  • Quetiapine or a pharmaceutically acceptable salt may be administered in conjunction with one or more other agents useful for treating diabetes.
  • Quetiapine or a pharmaceutically acceptable salt may be administered in conjunction with one or more other agents useful for treating psychoses. As indicated above, where quetiapine or a pharmaceutically acceptable salt is administered in conjunction with another agent it may be administered simultaneously, sequentially or separately with that other agent or agents. Thus, as indicated above, quetiapine or a pharmaceutically acceptable salt may be formulated with the other agent or agents or may be presented as a separate formulation.
  • a pharmaceutical composition comprising quetiapine or a pharmaceutically acceptable salt and an agent known for treating diabetes together with a pharmaceutically acceptable diluent or carrier.
  • composition comprising quetiapine or a pharmaceutically acceptable salt and an agent for treating diabetes for simultaneous, sequential or separate administration.
  • quetiapine was used as the fumarate (2:1) salt.
  • Body weight data were collected for a group of 65 randomly-selected schizophrenic patients who were on clozapine initially (200 - 800 mg/day for 6 months) and then had quetiapine added to their therapy. Weights were recorded monthly, and status of diabetes follow-up was also performed. Clozapine dosages were reduced as quetiapine was added. The duration of treatment with quetiapine was 10 months. Data were extracted from retrospective chart review of 65 patients who were prospectively assigned to clozapine- quetiapine therapy.
  • Patients received a mean quetiapine dosage of approximately 475 mg/day after one year of open-label treatment. Only one patient withdrew from the open-label study due to an adverse event of weight gain.
  • quetiapine is its apparent capability of being associated with minimal weight gain unlike olanzapine and clozapine.
  • the above formulations may be obtained by conventional procedures well known in the pharmaceutical art.
  • the tablets may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.
  • a preferred formulation is that available commercially as quetiapine fumarate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

A method of treating weight in patients, in particular those suffering from psychoses, by administering the antipsychotic agent quetiapine.

Description

METHOD OF TREATMENT
This invention relates to a method of treating the weight of patients and is particularly concerned with a method of treating the weight of patients suffering from psychoses. Schizophrenia is a chronic and debilitating illness that affects approximately 1% of the population worldwide. For many years, conventional antipsychotic agents have been widely used to treat schizophrenia; however, they are associated with undesirable motor symptoms (extrapyramidal symptoms [EPS]) such as akathisia, dyskinesia, bradykinesia and parkinsonism, which are known to contribute to poor compliance with treatment. Such adverse effects of the older, typical antipsychotics caused a great deal of distress to patients but were tolerated as being inevitable in the treatment of psychotic symptoms. Even so, studies have suggested that 40% of patients stopped taking their medication within 1 year and 75% of patients stopped within 2 years (Perkins, 1999, J. Clinical Psychiatry 60 (suppl. 21), pp 25-30). Many of the newer, atypical antipsychotic agents have an improved tolerability profile.
With the resulting diminution in prevalence of the very debilitating EPS, more attention is being focused on other side effects of these agents, including a propensity to induce weight gain, seen with most atypical antipsychotics to a greater or lesser degree (Wirshing et al, 1999, J. Clinical Psychiatry 60: 358-63). In some cases, this may adversely affect patients' quality of life and possibly treatment compliance.
It has been recognized for more than 40 years that there is an association between antipsychotic medication and weight gain. In the past, weight gain has been linked to efficacy of antipsychotic medication, with research linking a positive outcome with increased weight. However, more recent research has shown this not to be the case (Umbricht et al, 1994, J. Clinical Psychiatry 55 (suppl. B): 157-60; Bustillo et al, 1996, American J. Psychiatry 153: 817-9).
Weight gain is associated with increased morbidity and mortality from a wide range of conditions including hypertension, coronary heart disease, cerebrovascular disease, type 2 diabetes mellitus, various cancers, sleep apnea and respiratory problems. It is also linked with morbidity related to the disease being treated itself. Studies have shown that the side effect of weight gain causes relatively more distress than many of the other common side effects associated with antipsychotic medication (Weiden, 1999). If weight gain is considered by the patient to be unacceptable, compliance with the antipsychotic may be reduced and a worsening of the psychotic condition may ensue.
The extent to which each of these antipsychotic agents is associated with weight gain varies considerably (Allison et al, 1999, Am. J. Psychiatry 156: 1686-96; Wirsching et al, 1999). Weight gains of 3.99, 3.51 and 2.00 kg have been estimated following 10 weeks treatment with clozapine, olanzapine and risperidone, respectively (Allison et al, 1999).
Simansky et al, (Am. Psychiatry Association Meeting, Washington, USA, May, 1999) report on weight gains associated with treatment using ziprasidone, risperidone, quetiapine, olanzapine or clozapine. They confirm that the largest weight gains are associated with treatment using olanzapine or clozapine. They report that quetiapine is associated with a weight gain greater to that seen with risperidone and greater than that seen with ziprasidone.
However, this report is based on an extrapolation to a ten week period based on an estimate at week 6 of treatment.
We have unexpectedly found that quetiapine is associated with a small mean weight increase in the first 5-6 weeks of treatment with little further mean change observed over 12 months of treatment. Actual mean weight increase for quetiapine treated patients differs markedly from the extrapolated figures reported by Simansky et al.
According to the present invention, there is provided a method of treating the weight of a patient which comprises administering an effective amount of quetiapine or a pharmaceutically acceptable salt thereof to said patient.
In another aspect, the present invention provides quetiapine or a pharmaceutically acceptable salt thereof for use in treating the weight of a patient.
In yet a further aspect, the present invention provides the use of quetiapine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating the weight of a patient.
Quetiapine is l l-(4-[2-(2-hydroxyethoxy)ethyl]-l-piperazinyl)- dibenzo[b,fJ[1.4]thiazepine. This compound pharmaceutically acceptable salts thereof and use in treating schizophrenia are described in granted European Patent No. EP 240,228.
In particular, the patient is suffering from psychoses. It is well recognized that there is a link between obesity and diabetes, especially type IT diabetes, and that moderate to severe obesity increases the risk of developing diabetes. It is also widely accepted that weight loss results in metabolic improvement and hence in glycaemic control and insulin sensitivity which in turn give rise to improvements in cardiovascular risk factors. This is reported by, for example, Bosello et al, Int. J. of Obesity,
(1997) 21, Suppl 1, S10-13.
Weight gain in patients is generally undesirable but is more so in patients who are diabetic or who are at risk from developing diabetes. Accordingly, the present invention further provides a method of treating the weight of a patient who is exhibiting diabetes or is at risk from developing diabetes which method comprises administering an effective amount of quetiapine or a pharmaceutically acceptable salt thereof to said patient. In particular, the patient is suffering from psychoses.
In an alternative aspect of the present invention, there is also provided a method of treating psychoses in a patient who is diabetic or who is at risk from developing diabetes which method comprises administering an effective amount of quetiapine or a pharmaceutically acceptable salt thereof to said patient.
In particular the patient is diabetic, that is exhibiting one or more of the symptoms of diabetes. Quetiapine and pharmaceutically acceptable salts thereof are particularly effective in inducing weight loss in patients who have tended to gain weight when treated with other antipsychotics such as clozapine or olanzapine, in particular clozapine. Under such circumstances, quetiapine or pharmaceutically acceptable salts thereof may reverse at least part of any weight gained as a result of treatment with the antipsychotic such as clozapine or olanzapine, in particular clozapine.
In a particular aspect, the dosage of the other antipsychotic agent, such as clozapine or olanzapine, is decreased during treatment with quetiapine or pharmaceutically acceptable salt thereof.
The method of treatment of the present invention relates to short term (5-6 weeks), medium term (1-6 months) and long term (6 months-2 years or more) treatment, and is particularly valuable in medium term and long term treatment.
Quetiapine may be administered as the compound, 1 l-(4-[2-(2-hydroxyethoxy)ethyl]- l-piperazinyl)-dibenzo[b,f][1.4]thiazepine or may be administered in the form of a pharmaceutically acceptable salt. Examples of suitable salts include, for example, chloride, maleate, fumarate, citrate, phosphate, methane sulphonate and sulphate salts. Preferred salts include fumarates and a particularly preferred salt is the hemi-fumarate. It is generally preferred that 1 l-(4-[2-(2-hydroxyethoxy)ethyl]-l-piperazinyi)- dibenzo[b,f][1.4]thiazepine is administered in the form of a pharmaceutically acceptable salt, and in particular a fumarate (2:1) salt.
In the treatment of the diseases and conditions mentioned above quetiapine or a pharmaceutically acceptable salt may be administered orally or parenterally in a conventional dosage form such as tablets, pills, capsules, injectables or the like. The dosage in mg/kg of body weight of the compound used to treat mammals will vary according to the size of the mammal and particularly with respect to the brain/body weight ratio. In general, a higher mg/kg dosage for a small animal such as a dog will have the same effect as a lower mg/kg dosage in an adult human. A minimum effective dosage for quetiapine or a pharmaceutically acceptable salt thereof will be at least about 1.0 mg/kg of body weight per day for mammals with a maximum dosage for a small mammal such as a dog, of about 200 mg/kg per day. For humans, a dosage of about 1.0 to 40 mg/kg per day will generally be effective. Typically, a dosage of about 25mg to 800mg per day will generally be effective. Usually, a dosage of about 150mg to 750mg per day will be administered, with a convenient dosage being about 300mg per day. In some groups of patients a lower dosage may be preferred such as lOOmg per day. The dosage can be given once daily or in divided doses, for example, 2 to 4 doses daily. The dose may be conventionally formulated in an oral or parenteral dosage form by compounding 25 to 500 mg per unit dosage of conventional vehicle, excipient, binder, preservative, stabilizer, flavor or the like as called for by accepted pharmaceutical practice, for example, as described in US Patent 3,755,340.
Quetiapine or a pharmaceutically acceptable salt may be used in pharmaceutical compositions as the sole active ingredient or may be contained in a pharmaceutical composition together with one or more other active ingredients, or it may be co-administered with one or more known drugs.
Quetiapine or a pharmaceutically acceptable salt may be administered in conjunction with one or more other agents useful for treating diabetes.
Quetiapine or a pharmaceutically acceptable salt may be administered in conjunction with one or more other agents useful for treating psychoses. As indicated above, where quetiapine or a pharmaceutically acceptable salt is administered in conjunction with another agent it may be administered simultaneously, sequentially or separately with that other agent or agents. Thus, as indicated above, quetiapine or a pharmaceutically acceptable salt may be formulated with the other agent or agents or may be presented as a separate formulation.
Thus, in one aspect of the present invention, there is provided a pharmaceutical composition comprising quetiapine or a pharmaceutically acceptable salt and an agent known for treating diabetes together with a pharmaceutically acceptable diluent or carrier.
In a further aspect there is provided a pharmaceutical composition comprising quetiapine or a pharmaceutically acceptable salt and an agent for treating diabetes for simultaneous, sequential or separate administration.
The preparation of 1 l-(4-[2-(2-hydroxyethoxy)ethyl]-l-piperazinyl)- dibenzo[b,fJ[l .4]thiazepine and its pharmaceutically acceptable salts is described in, for example, granted European Patents Nos. EP 240,218; EP 282,236 and in International Patent
Application No. PCT/GB98/02260. This compound is commercially available under the generic name quetiapine fumarate.
The invention will now be illustrated with reference to the following, non-limiting examples in which quetiapine was used as the fumarate (2:1) salt..
Example 1
Body weight data were collected for a group of 65 randomly-selected schizophrenic patients who were on clozapine initially (200 - 800 mg/day for 6 months) and then had quetiapine added to their therapy. Weights were recorded monthly, and status of diabetes follow-up was also performed. Clozapine dosages were reduced as quetiapine was added. The duration of treatment with quetiapine was 10 months. Data were extracted from retrospective chart review of 65 patients who were prospectively assigned to clozapine- quetiapine therapy. All 65 patients showed weight loss ranging from 0.5 to 23 lbs, with a mean loss of 3.98 lbs, after the first month of combination treatment; the quetiapine dose at one month ranged from 200 - 800 mg/day. The improvement continued throughout the 10- month study period. Total weight loss ranged from 1 to 41 lbs, with a mean loss of 9.2 lbs over the course of the study. Twenty per cent of patients developed diabetes during clozapine monotherapy and each showed significant improvement of diabetes with addition of quetiapine, as assessed through monthly blood monitoring and clinical improvement.
Thus, an unexpected clinical effect of quetiapine is its apparent propensity to induce weight loss and help with diabetes management in patients who gain weight and develop diabetes on clozapine. Example 2
427 patients (277 male; 150 female) were treated with quetiapine monotherapy during controlled and open-label extension studies for up to 3.5 years and weight changes were monitored at specified time intervals throughout this period. The patients were in the age range 18-75 with a mean age of 37.3 years.
Patients were grouped using an observed cases approach within specified time intervals. Data on patients who received quetiapine monotherapy during the controlled portion of the trial and/or quetiapine during the open-label extension period are reported. Data were obtained for 30% of patients for at least one year. Over the first 4 weeks, a mean weight loss of 0.36 Kg (n=17) was recorded. At subsequent time intervals weight changes were -0.17 kg (n=49) at weeks 5-8; +1.58 kg (n=171) at weeks 9-13; +0.29 kg(n=153) at weeks 14-26; +1.73 kg (n=128) at weeks 27-39; -1.47 kg (n=37) at weeks 40-52; +2.00 kg (n=l 16) at weeks 53-78; +3.43 kg (n=64) at weeks 79-104; +3.45 kg (n=44) at weeks 105-130 and +0.36 kg (n=9) at weeks 131-156. Patients received a mean quetiapine dosage of approximately 475 mg/day after one year of open-label treatment. Only one patient withdrew from the open-label study due to an adverse event of weight gain.
Thus, an unexpected clinical effect of quetiapine is its apparent capability of being associated with minimal weight gain unlike olanzapine and clozapine.
Example 3
The following illustrates representative pharmaceutical dosage forms containing the compound l l-(4-[2-(2-hydroxyethoxy)ethyl]-l-piperazinyl)-dibenzo[b,f][l,4]thiazepine fumarate (2:1). (a) Tablet mg tablet
Quetiapine fumarate 50.0
Mannitol, USP 223.75
Croscarmellose sodium 6.0
Maize starch 15.0 Hydroxypropylmethylcellulose (HPMC), 2.25
Magnesium stearate 3.0 (b) Capsule
Quetiapine fumarate 10.0
Mannitol, USP 488.5
Croscarmellose sodium 15.0 Magnesium stearate 1.5
The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate. A preferred formulation is that available commercially as quetiapine fumarate.

Claims

I . A method of treating the weight of a patient which comprises administering an effective amount of quetiapine or a pharmaceutically acceptable salt thereof to said patient.
2. A method according to claim 1 wherein the patient is suffering from psychoses.
3. A method according to claim 1 or 2 wherein the patient is exhibiting diabetes or is at risk from developing diabetes.
4. A method according to any one of claims 1 to 3 wherein the patient treated with another antipsychotic agent.
5. A method according to claim 4 wherein the antipsychotic agent is clozapine or olanzapine.
6. A method according to claim 5 wherein the antipsychotic agent is clozapine.
7. A method according to any one of claims 4 - 6 wherein the dosage of the other antipsychotic agent is decreased during treatment with an effective amount of quetiapine or a pharmaceutically acceptable salt thereof.
8. A method according to claim 7 wherein the dosage of the other antipsychotic agent is decreased to zero.
9. A method of inducing weight loss in a patient suffering from psychoses who has previously been treated with an antipsychotic agent which comprises administering an effective amount of quetiapine or a pharmaceutically acceptable salt thereof to said patient.
10. A method according to claim 9 wherein the antipsychotic agent was clozapine or olanzapine.
I I . Quetiapine or a pharmaceutically acceptable salt thereof for use in treating the weight of a patient. 12. The use of quetiapine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating the weight of a patient.
EP00927593A 1999-05-19 2000-05-16 Method of treating weight gain Withdrawn EP1223939A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9911499 1999-05-19
GBGB9911499.3A GB9911499D0 (en) 1999-05-19 1999-05-19 Medicament
GB0002762A GB0002762D0 (en) 2000-02-08 2000-02-08 Method of treatment
GB0002762 2000-02-08
PCT/GB2000/001875 WO2000071106A2 (en) 1999-05-19 2000-05-16 Method of treating weight gain

Publications (1)

Publication Number Publication Date
EP1223939A1 true EP1223939A1 (en) 2002-07-24

Family

ID=26243587

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00927593A Withdrawn EP1223939A1 (en) 1999-05-19 2000-05-16 Method of treating weight gain

Country Status (6)

Country Link
EP (1) EP1223939A1 (en)
JP (1) JP2003500353A (en)
AU (1) AU4598400A (en)
CA (1) CA2363784A1 (en)
HK (1) HK1048440A1 (en)
WO (1) WO2000071106A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1795199A3 (en) * 2001-02-06 2007-07-25 AstraZeneca AB Quetiapine for the treatment of substance dependence or substance abuse
US7304047B2 (en) 2001-02-06 2007-12-04 Astrazeneca Ab Method of treating substance abuse with quetiapine
AU2002319665B2 (en) * 2001-07-23 2006-09-21 Corcept Therapeutics, Inc. Methods for preventing antipsychotic-induced weight gain
JP2007533733A (en) * 2004-04-22 2007-11-22 モル リサーチ アプリケーションズ リミテッド How to control food intake

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9604465D0 (en) * 1996-03-01 1996-05-01 Smithkline Beecham Plc Novel method
GB9615767D0 (en) * 1996-07-26 1996-09-04 Smithkline Beecham Plc Novel treatment
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
AU3757500A (en) * 1999-03-18 2000-10-04 Childrens Hospital Research Foundation A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0071106A2 *

Also Published As

Publication number Publication date
WO2000071106A2 (en) 2000-11-30
JP2003500353A (en) 2003-01-07
HK1048440A1 (en) 2003-04-04
CA2363784A1 (en) 2000-11-30
AU4598400A (en) 2000-12-12
WO2000071106A3 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
KR102240240B1 (en) Pharmaceutical combination comprising DAPAGLIFLOZIN L-PROLINE and antidiabetic drugs
JP2014167026A (en) Pharmaceutical composition
TW201632511A (en) Compositions and methods for treating schizophrenia
JPH0761923A (en) Therapeutic agent for alzheimer disease
JP6499634B2 (en) Combination of solifenacin and salivary stimulant for the treatment of overactive bladder
KR100709528B1 (en) Pharmaceutical composition for blood sugar control
WO2000071106A2 (en) Method of treating weight gain
JP3872834B2 (en) Maillard reaction inhibitor
EP1345610B1 (en) Quetiapine for treating of dyskinesia in non-psychotic patients
EP0604853A2 (en) Pharmaceutical composition for preventing or treating arteriosclerosis
US20240100011A1 (en) Pediatric formulations of ferric citrate
US20080108597A1 (en) New Use of Quetiapine
WO2007058335A1 (en) Use of tak-475 together with ezetimibe for treating hyperlipidemia
EP1359919B1 (en) Use of quetiapine for the treatment of cocaine dependence
JP3243514B2 (en) Therapy-a drug for the treatment of refractory schizophrenia
KR20090024248A (en) Pharmaceutical formulations and compositions of selective antagonists of CBCR2 or selective antagonists of both CBCR1 and CBCR2, and methods of use thereof for treating inflammatory diseases
WO2020014072A1 (en) Neostigmine pharmaceutical combination for treating myasthenia gravis
KR102490653B1 (en) Pharmaceutical composition comprising dapagliflozin and glimepiride
WO2019023175A1 (en) Pharmaceutical compositions and methods utilizing neostigmine and a nk-1 antagonist for treating myasthenia gravis
EP4536191A1 (en) Ebselen containing oral dosage forms
AU2006215444A1 (en) Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
CN101316589A (en) Treatment of diabetes
HK1057170B (en) Quetiapine for treating of dyskinesia in non-psychotic patients
HK1056120B (en) Use of quetiapine for attention deficit hyperactivity disorder or conduct disorder
EA040638B1 (en) PHARMACEUTICAL COMPOSITION CONTAINING 2-((1-(2-(4-FLUOROPHENYL)-2-OXOETHYL)PIPERIDIN-4-YL)METHYL)ISOINDOLINE-1-ONE FOR TREATMENT OF PSYCHONEUROLOGICAL DISEASE OR SLEEP DISORDER, METHOD FOR TREATMENT OF PSYCHONEUROLOGICAL DISEASE OR SLEEP DISORDER SLEEP, TABLET AND SET

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20040629

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050111